Key Decisions in HIV Care

Download All
Learn the latest data and perspectives on HIV prevention strategies such as guideline recommendations for PrEP, overcoming barriers, improving access, and more.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
person default
Anonymous Patient
person default
Jason Schafer, PharmD, MPH
Don Smith, MD

Prevention

Learn how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Download this PDF to share with your patients who are interested in HIV pre-exposure prophylaxis

person default Jason Schafer, PharmD, MPH Released: February 24, 2022

Listen as Latesha Elopre, MD, MSPH, explains how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: July 7, 2021

See how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Learn key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: February 15, 2022

Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

person default Jason Schafer, PharmD, MPH Released: March 14, 2022

Learn key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: February 15, 2022

In this case example, learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

person default Jason Schafer, PharmD, MPH Released: February 8, 2022

Important considerations for PrEP in transgender individuals include choosing the right PrEP option and addressing stigma to improve adherence.

Karine Lacombe, MD, PhD Released: April 15, 2022

Learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

person default Jason Schafer, PharmD, MPH Released: February 16, 2022

As a gay man who is also a physician, I am considering long-acting PrEP but have many questions about how it would work in my life.

person default Anonymous Patient Released: February 3, 2022

Adherence and accessibility are critical to improving uptake and effectiveness of PrEP for PWID.

Karine Lacombe, MD, PhD Released: April 15, 2022

In this case example, learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.

Released: February 16, 2022

Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.

person default Jason Schafer, PharmD, MPH Released: March 21, 2022

Learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.

person default Jason Schafer, PharmD, MPH Released: March 15, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: March 24, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: March 25, 2022

Australian study shows overwhelming demand and uptake of PrEP and highlights the power of partnering among government, clinical, and academic institutions.

Don Smith, MD Released: March 18, 2022

In this case example, learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Listen as Dr Michelle D. Collins-Ogle shares data and recommendations for HIV PEP, including currently recommended regimens, single-tablet regimens, and pre-exposure prophylaxis following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: May 26, 2022
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings